Sad story. A useful & potentially valuable technology for serious medical applications was misdirected into headache treatment as a result of strategic business incompetence. The result is several years of business failure & loss of shareholder value. That failure is now being compounded by a push into DTC sector in which ECOR lacks strengths for success. ECOR should go private & regroup. At least execs are getting paid.